How Does Gene Therapy Work Process Risks And Cost?

Gene therapy works by delivering genetic material into a patient’s cells to correct, replace, or compensate for a faulty gene. The process involves extracting or targeting cells, inserting a working copy of the gene using a modified virus or other delivery method, and returning or activating those cells in the body. Approved gene therapies carry real risks, including immune reactions and organ damage, and costs routinely exceed $1 million per treatment in the United States.

How Does Gene Therapy Work at the Cellular Level?

Every gene therapy starts with the same basic idea: put functional genetic instructions into cells that need them. How that happens depends on the approach.

There are two main strategies. In vivo therapy delivers the gene directly into the body, usually through an injection or infusion. Ex vivo therapy removes cells from the patient, modifies them in a laboratory, and returns them. Each method has distinct advantages and limitations.

The Role of Vectors

Genes cannot simply be injected into cells on their own. They need a carrier, called a vector. Most approved therapies use modified viruses because viruses evolved to insert genetic material into human cells.

The most common vector is adeno-associated virus, or AAV. AAV vectors are stripped of viral genes that cause disease and loaded with the therapeutic gene instead. Other approaches use lentiviruses, which can integrate genetic material into the cell’s DNA. Some newer methods use lipid nanoparticles — the same technology used in certain mRNA vaccines — to deliver genetic instructions without a virus at all.

One clarification that often gets lost: gene therapy does not always mean fixing a broken gene in place. Sometimes it means adding a working copy of a gene while the faulty version remains. Sometimes it means silencing a gene that is overactive. And in some cases, it means editing existing DNA directly using tools like CRISPR.

What Are the Steps in the Gene Therapy Process?

The process varies by treatment, but most follow a recognizable sequence.

• Evaluation and testing. Doctors confirm the diagnosis, check which genetic variant is involved, and assess whether the patient meets eligibility criteria for a specific therapy.
• Cell collection or direct delivery planning. For ex vivo therapies, blood or bone marrow cells are collected. For in vivo therapies, the care team plans the infusion or injection.
• Vector manufacturing. The therapeutic gene is packaged into a vector in a specialized laboratory. This step can take weeks.
• Conditioning (for some therapies). Certain ex vivo treatments require chemotherapy or other drugs to make room for the modified cells in the bone marrow. This step carries its own significant risks.
• Administration. The therapy is given by infusion or injection, often in a hospital setting.
• Monitoring. Patients are watched closely for immune reactions, organ toxicity, and other complications. Follow-up can last years.

The timeline from evaluation to treatment varies widely. Some therapies can be delivered within weeks of approval. Others take months because of manufacturing and conditioning requirements.

What Are the Risks of Gene Therapy?

Gene therapy carries serious risks. This is not a treatment category where the downsides are rare or minor.

Immune reactions are among the most concerning. The immune system can attack the vector itself, leading to inflammation, organ damage, or in rare cases, death. Severe immune responses have been documented in clinical trials and in approved treatments.

Insertional mutagenesis is a risk when vectors integrate into the genome. If the genetic material lands in the wrong spot, it could disrupt a gene that controls cell growth, potentially leading to cancer. This has occurred in early gene therapy trials, though newer vector designs have reduced — but not eliminated — this risk.

Off-target effects occur when gene editing tools modify DNA at unintended locations. The consequences depend on where those edits land.

Loss of effect over time is another limitation. Some gene therapies provide lasting benefit. Others diminish as modified cells die or the body clears the vector. Long-term durability data for many approved therapies is still limited.

There is also the risk of the procedure itself. Conditioning chemotherapy before ex vivo therapy can cause infertility, increase infection risk, and damage organs. These are not hypothetical concerns — they are documented effects.

How Much Does Gene Therapy Cost?

Approved gene therapies in the United States are among the most expensive treatments in medicine. List prices for several approved therapies exceed $2 million per patient for a one-time treatment. Others fall in the $400,000 to $1 million range.

These figures represent the drug cost alone. They do not include hospitalization, conditioning regimens, monitoring, or management of complications. The total cost of care can be substantially higher.

Insurance coverage varies. Some insurers cover approved therapies for eligible patients. Others do not, or they impose strict prior authorization requirements. Government programs like Medicaid may cover gene therapies, but coverage rules differ by state.

Manufacturers have introduced outcomes-based agreements in some cases, where payment is tied to whether the therapy works. These arrangements are not universal, and their long-term impact on patient access is not yet clear.

Which Diseases Can Gene Therapy Treat Today?

The list of approved gene therapies has grown, but it remains narrow relative to the number of genetic diseases that exist.

Approved therapies target conditions including certain inherited retinal diseases, spinal muscular atrophy, specific types of leukemia and lymphoma, hemophilia, and a rare inherited disorder affecting lipid metabolism. Several additional therapies are approved for other rare conditions.

Most approved treatments address rare diseases caused by a single gene variant. Common diseases like diabetes, heart disease, and most cancers are not currently treatable with gene therapy outside of clinical trials.

Hundreds of clinical trials are underway. Some target more common conditions. But trial participation does not guarantee benefit, and many trials fail to show meaningful results.

Is Gene Therapy a Cure?

Sometimes. Often not. It depends entirely on the disease and the specific therapy.

For some conditions — certain inherited retinal diseases, for example — a single treatment has produced lasting improvement in vision for some patients. For others, the benefit is temporary or partial. Some therapies extend survival without eliminating the disease.

The word “cure” gets used loosely in gene therapy discussions. A more accurate framing: some therapies modify the course of a disease in ways that were not previously possible. Whether that constitutes a cure depends on how you define the term and how long the effect lasts.

Long-term follow-up data for most approved therapies spans years, not decades. It is not yet known whether benefits will persist for a patient’s lifetime.

What Is the Difference Between Gene Therapy and Gene Editing?

Gene therapy is the broader category. Gene editing is one method within it.

Traditional gene therapy adds a working copy of a gene or replaces a faulty one using a vector. It does not necessarily change the patient’s existing DNA. Gene editing, by contrast, uses tools like CRISPR to cut, remove, or rewrite specific sequences in the genome.

Both approaches can be delivered ex vivo or in vivo. Both carry risks. Gene editing has the theoretical advantage of precision, but off-target edits remain a concern, and long-term safety data is limited.

As of now, only a small number of gene editing therapies have received regulatory approval. Most remain in clinical trials.